Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 5Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 5

Conditions

Ovarian Neoplasms 9Fallopian Tube Neoplasms 8Breast Neoplasms 6Neoplasms 5Carcinoma, Ovarian Epithelial 5Recurrence 3Prostatic Neoplasms 3Endometrial Neoplasms 3Small Cell Lung Carcinoma 2Metastatic Castration Resistant Prostate Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Lung Neoplasms 1Genital Neoplasms, Male 1Genital Neoplasms, Female 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Gastric Cancer 1Adenocarcinoma, Clear Cell 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasms × rucaparib × Clear all
NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT03521037 2023-06-09

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

pharmaand GmbH

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

pharmaand GmbH

Phase 1 Completed
36 enrolled
Tumor-Agnostic

Neoplasms

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

University Hospital, Caen

Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡